¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"phase shift mutation"¿¡ ´ëÇÑ °æºÏ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°³»°úÇб³½Ç »çÀü ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
3
¿µ¹®
ÇѱÛ
¼³¸í
mutation disturbance
º¯¼º Àå¾Ö
mutation rate
º¯ÀÌÀ², µ¹¿¬º¯ÀÌÀ²
ochre mutation
¿À¿ìÄ¿ µ¹¿¬º¯ÀÌ
reading framework mutation
ÆÇµ¶ °ñ°Ý ±¸Á¶ À̵¿ µ¹¿¬º¯ÀÌ
reverse mutation
ȯ¿ø µ¹¿¬ º¯ÀÌ
silent mutation
¹«ÁõÈÄ µ¹¿¬º¯ÀÌ
somatic mutation
ü ¼¼Æ÷ µ¹¿¬º¯ÀÌ
suppressor mutation
¾ïÁ¦ µ¹¿¬º¯ÀÌ
temperature-sensitive mutation
¿Âµµ ¹Î°¨ µ¹¿¬º¯ÀÌ
visible mutation
°¡½Ã¼º µ¹¿¬º¯ÀÌ
accelerated death phase
°¡¼Ó »ç¸ê±â
acceleration phase
ÃËÁø±â, °¡¼Ó±â
¹Ì»ý¹° ¹è¾ç ½Ã °©Àڱ⠼ºÀåÀÌ Áõ°¡ÇÏ´Â ½Ã±â.
acute phase protein
±Þ¼º±â ´Ü¹éÁú
°¨¿°À̳ª Á¶Á÷ ¼Õ»óÀÌ ÀÖÀ» ¶§ Á¤»óº¸´Ù 2-100¹è Á¤µµ Áõ°¡ÇÏ´Â Ç÷Àå ´Ü¹éÁúÀ» ÃÑĪÇÏ¿© APP¶ó°í ÇÏ¸ç ¼±Ãµ¼º ¸é¿ª¿¡ °ü¿©ÇÑ´Ù.
acute phase reaction
±Þ¼º±â ¹ÝÀÀ
acute phase serum
±Þ¼º º´±â Ç÷û
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
3
¿µ¹®
ÇѱÛ
¼³¸í
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½